ARVN
Arvinas, Inc.
There isn't enough reported data to score ARVN yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ARVN Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Unavailable |
ARVN's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ARVN PE Valuation
ARVN has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ARVN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect ARVN's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ARVN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.10 | +$0.71 |
| Q2 2026 | $0.24 | +$1.25 |
| Q1 2026 | -$3.18 | -$2.52 |
| Q4 2025 | -$1.14 | +$1.63 |
| Q3 2025 | -$0.81 | +$3.86 |
| Q2 2025 | -$1.01 | +$4.16 |
| Q1 2025 | -$0.66 | +$5.27 |
| Q4 2024 | -$2.77 | +$3.73 |
ARVN has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ARVN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $500K | -99% |
| Q2 2026 | $249.7M | +1015% |
| Q1 2026 | $15.6M | -92% |
| Q4 2025 | $9.5M | -84% |
| Q3 2025 | $41.9M | -59% |
| Q2 2025 | $22.4M | -71% |
| Q1 2025 | $188.8M | +646% |
| Q3 2024 | $102.4M | +196% |
ARVN's revenue is shrinking: $500,000 last quarter, down 99% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -11820% | -11716 points |
| Q2 2026 | 66% | +385 points |
| Q1 2026 | -409% | -447 points |
| Q4 2025 | -785% | -687 points |
| Q3 2025 | -105% | -46 points |
| Q2 2025 | -319% | -256 points |
| Q1 2025 | 38% | +367 points |
| Q4 2024 | -98% | N/A |
ARVN's operating margin was −11820% last quarter, down 11715 points from the same quarter a year ago, near the bottom of its range since 2019.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ARVN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over ARVN on profitability, with a higher operating margin.
ARVN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$10.2M | +$49M |
| Q2 2026 | -$48.5M | +$48.1M |
| Q1 2026 | -$70.5M | +$18.8M |
| Q4 2025 | -$30.6M | +$53.8M |
| Q3 2025 | -$59.2M | +$69.5M |
| Q2 2025 | -$96.6M | -295% |
| Q1 2025 | -$89.3M | +$8.3M |
| Q4 2024 | -$84.4M | -$1.2M |
ARVN has burned cash in almost every quarter: −$160M over the past year, against −$330M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ARVN on cash generation, producing positive trailing cash flow while its opponent burns cash.
ARVN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.5% | -300K shares |
| 1 year | -11% | -7.8M shares |
| 3 years | +21% | +11.3M shares |
| 5 years | +31% | +15.6M shares |
| Available history | +75% | +28.1M shares |
ARVN has the edge over HIMS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $74.1M |
| Q4 2023 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has 234M diluted shares, down 6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ARVN Net Leverage
ARVN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ARVN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.8 | Neutral |
| Stochastic | 18.1 | Oversold |
ARVN's weekly RSI is 39 (neutral) and its Stochastic is 18 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ARVN PE vs Healthcare Sector
| Metric | ARVN | Sector median | Relative |
|---|---|---|---|
| PE | 33x | 26x | 27% above |
ARVN has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ARVN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $7.26 | 5.4% below |
| 20 week MA | $8.06 | 15% below |
| 50 week MA | $9.82 | 30% below |
| 100 week MA | $10.2 | 33% below |
| 200 week MA | $19.7 | 65% below |
ARVN is in a downtrend: it's below all five of its weekly moving averages, and 65% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ARVN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $41.8 | $82.2 | +97% |
| 2021 | $82.2 | $81.3 | -1.2% |
| 2022 | $81.3 | $32.7 | -60% |
| 2023 | $32.7 | $41.2 | +26% |
| 2024 | $41.2 | $19.0 | -54% |
| 2025 | $19.0 | $12.2 | -36% |
| 2026 YTD | $12.2 | $6.87 | -44% |
ARVN has finished lower in four of the last six years. It's down 44% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over ARVN on returns for 2026, with the stronger performance.